Liquid Biopsy Evaluation and Repository Development at Princess Margaret
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
The objective of this protocol is to develop an institution-wide liquid biopsy protocol that
 will establish a common process for collecting blood and corresponding archived tumor
 specimens for future research studies at the University Health Network's Princess Margaret
 Cancer Centre. Circulating cell-free nucleic acids (cfNA), including cell-free DNA (cfDNA)
 and cell-free RNA (cfRNA), are non-invasive, real-time biomarkers that can provide diagnostic
 and prognostic information before cancer diagnosis, during cancer treatment, and at disease
 progression. Cancer research scientists and clinicians at the Princess Margaret are
 interested in incorporating the collection of peripheral blood samples ("liquid biopsies")
 into research protocols as a means of non-invasively assessing tumor progression and response
 to treatment at multiple time points during a patient's course of disease.
Inclusion Criteria:

 1. Patients with either histological confirmation of a solid tumor or hematological
 malignancy, OR patients identified as high-risk for cancer (based on identified
 aberration in cancer predisposition gene or on hormonal and/or family history without
 known aberration).

 2. Patient must be ≥ 18 years old.

 3. All patients must have signed and dated an informed consent form for this LIBERATE
 study.

 4. If patients are being co-consented for a separate primary research study listed in
 Appendix I, they must fulfill the eligibility criteria for that separate primary
 research study. If there is a discrepancy in the eligibility criteria between
 protocols, the separate primary research study's criteria take precedence.

 Exclusion Criteria:

 None